MCRB Stock - Seres Therapeutics, Inc.
Unlock GoAI Insights for MCRB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $144.93M | $33.22M |
| Gross Profit | $-3,532,000 | N/A | N/A | $144.93M | $-57,355,000 |
| Gross Margin | N/A | N/A | N/A | 100.0% | -172.7% |
| Operating Income | $-121,315,000 | $-195,097,000 | $-179,914,000 | $-64,493,000 | $-88,130,000 |
| Net Income | $136,000 | $-113,724,000 | $-250,157,000 | $-65,578,000 | $-89,127,000 |
| Net Margin | N/A | N/A | N/A | -45.2% | -268.3% |
| EPS | $-18.86 | $-17.77 | $-46.29 | $-14.30 | $-22.34 |
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 8th 2025 | Chardan Capital Markets | Downgrade | Neutral | $6 |
| October 24th 2024 | JP Morgan | Downgrade | Underweight | - |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $12 |
| April 21st 2023 | JP Morgan | Initiation | Neutral | $7 |
Earnings History & Surprises
MCRBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-2.39 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.05 | $0.94 | +1780.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-2.72 | $-2.27 | +16.5% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.67 | $-2.24 | -234.3% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.17 | $-0.32 | -88.2% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-5.00 | $-6.60 | -32.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-5.60 | $-4.40 | +21.4% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-7.20 | $-5.40 | +25.0% | ✓ BEAT |
Q1 2024 | Mar 5, 2024 | $-8.00 | $-6.40 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-9.40 | $-7.40 | +21.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $11.00 | $7.20 | -34.5% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-11.40 | $-11.40 | 0.0% | = MET |
Q1 2023 | Mar 7, 2023 | $-8.20 | $-10.80 | -31.7% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-9.00 | $-9.80 | -8.9% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-11.60 | $-14.00 | -20.7% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-11.20 | $-12.20 | -8.9% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-9.00 | $-11.00 | -22.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-9.40 | $14.40 | +253.2% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-8.20 | $-10.60 | -29.3% | ✗ MISS |
Latest News
Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate
➖ NeutralSeres Therapeutics Secures Up To $3.6M CARB-X Funding To Develop Liquid SER-155 For Allo-HSCT Patients; Phase 1b Cut Bloodstream Infections 77%
📈 PositiveSeres Therapeutics To Feature New Post Hoc Data From SER-155 Phase 1b Trial In Oral Presentation At IDWeek 2025
➖ NeutralSeres Therapeutics Announces Actions To Reduce Operating Costs; Reducing Workforce By About 25%; Workforce Reduction To Result In Cash Charges Of $1M-$1.4M
📉 NegativeSeres Therapeutics Receives FDA Feedback To Finalize Phase 2 Protocol For SER-155 In Preventing BSIs In Allo-HSCT Patients
📈 PositiveFrequently Asked Questions about MCRB
What is MCRB's current stock price?
What is the analyst price target for MCRB?
What sector is Seres Therapeutics, Inc. in?
What is MCRB's market cap?
Does MCRB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MCRB for comparison